Aristo Pharmaceuticals Private Limited — Pioglitazone Exporter Profile
Indian Pharmaceutical Exporter · #9 for Pioglitazone · $721.0K export value · DGFT Verified
Aristo Pharmaceuticals Private Limited is the #9 Indian exporter of Pioglitazone with $721.0K in export value and 100 verified shipments. Aristo Pharmaceuticals Private Limited holds a 1.9% market share in Pioglitazone exports across 6 countries. The company exports 8 pharmaceutical products worth $19.4M across 8 therapeutic categories.
Aristo Pharmaceuticals Private Limited — Pioglitazone Export Profile: Buyers & Destinations
Where Does Aristo Pharmaceuticals Private Limited Export Pioglitazone?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UGANDA | $202.9K | 65 | 52.8% |
| TANZANIA | $122.3K | 14 | 31.8% |
| SUDAN | $28.7K | 10 | 7.5% |
| CHILE | $18.7K | 7 | 4.9% |
| BOLIVIA | $7.1K | 2 | 1.8% |
| KOREA,REPUBLIC OF | $4.6K | 2 | 1.2% |
Aristo Pharmaceuticals Private Limited exports Pioglitazone to 6 countries. The largest destination is UGANDA accounting for 52.8% of Aristo Pharmaceuticals Private Limited's Pioglitazone shipments, followed by TANZANIA (31.8%) and SUDAN (7.5%). These destinations reflect Aristo Pharmaceuticals Private Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Pioglitazone from Aristo Pharmaceuticals Private Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| NORVIK ENTERPRISES LIMITED | UGANDA | $146.4K | 30 |
| PLANET PHARMACEUTICAL LTD | TANZANIA | $119.1K | 12 |
| NORVIK ENTERPRISES LIMITED | UGANDA | $56.5K | 35 |
| PHARMA TRADING COMPANY BUILDING | SUDAN | $28.7K | 10 |
| SOUTH AMERICAN EXPRESS S.A. | CHILE | $18.1K | 6 |
| SOUTH AMERICAN EXPRESS S A | CHILE | $12.3K | 5 |
| PLANET PHARMACEUTICAL LTD, | TANZANIA | $3.2K | 2 |
Aristo Pharmaceuticals Private Limited supplies Pioglitazone to 7 buyers globally. The largest buyer is NORVIK ENTERPRISES LIMITED (UGANDA), followed by PLANET PHARMACEUTICAL LTD (TANZANIA) and NORVIK ENTERPRISES LIMITED (UGANDA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Pioglitazone Export Value and How Much Does Aristo Pharmaceuticals Private Limited Contribute?
India exported $35.2M worth of Pioglitazone through 2,674 shipments from 115 suppliers to 70 countries, serving 293 buyers globally. Aristo Pharmaceuticals Private Limited contributes $721.0K to this total, accounting for 1.9% of India's Pioglitazone exports. Aristo Pharmaceuticals Private Limited ships Pioglitazone to 6 countries through 7 buyers.
What Is the Average Shipment Value for Aristo Pharmaceuticals Private Limited's Pioglitazone Exports?
Aristo Pharmaceuticals Private Limited's average Pioglitazone shipment value is $7.2K per consignment, based on 100 shipments totaling $721.0K. The largest destination is UGANDA (52.8% of Aristo Pharmaceuticals Private Limited's Pioglitazone exports).
How Does Aristo Pharmaceuticals Private Limited Compare to Other Indian Pioglitazone Exporters?
Aristo Pharmaceuticals Private Limited ranks #9 among 115 Indian Pioglitazone exporters with a 1.9% market share. The top 3 exporters are AUROBINDO PHARMA LTD ($15.2M), AUROBINDO PHARMA LIMITED ($4.0M), INTAS PHARMACEUTICALS LIMITED ($3.4M). Aristo Pharmaceuticals Private Limited processed 100 shipments to 6 destination countries.
What Pioglitazone Formulations Does Aristo Pharmaceuticals Private Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PIOSAFE 30 (PIOGLITAZONE HYDROCHLORIDE TABLETS 30 MG) (15000 X 3 X 10'S = 450000 TABLETS) | $57.8K | 4 |
| PIOSAFE MF 15/500 (PIOGLITAZONE & METFORMIN HYDROCHLORIDE SUSTAINED RELEASE TBS15/500 MG) (2000 X 3 X 10'S = 60000 TBS) | $50.0K | 1 |
| PIOSAFE 30 (PIOGLITAZONE TABLETS USP 30MG) (1500 X 3 X 10'S= 45000 TBS) | $50.0K | 1 |
| PIOSAFE 30 (PIOGLITAZONE HYDROCHLORIDE TABLETS 30 MG) (1500 X 3 X 10'S = 45000 TABLETS) SAMPLES | $26.4K | 4 |
| PIOSAFE 30 (PIOGLITAZONE HYDROCHLORISE T | $25.1K | 2 |
| PIOSAFE MF 15/500 (PIOGLITAZONE & METFORMIN HCL SUSTAINED RELEASE TBS 15/500 MG) (200 X 3 X 10'S = 6000 TBS) SAMPLES | $13.8K | 1 |
| PIOSAFE MF 15/500 (PIOGLITAZONE & METFOR | $13.8K | 7 |
| PIOSAFE 30 (PIOGLITAZONE TABLETS USP 30MG) (150 X 3 X 10'S= 4500 TBS) SAMPLES | $9.2K | 1 |
| PIOSAFE 30 PIOGLITAZONE HYDROCHLORIDE TABLETS 30 MG 17450 X 3 X 10 S 523500 TABLETS | $8.9K | 1 |
| PIOSAFE MF 15/500(PIOGLITAZONE & METFORM | $8.9K | 2 |
Aristo Pharmaceuticals Private Limited exports 69 distinct Pioglitazone formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PIOSAFE 30 (PIOGLITAZONE HYDROCHLORIDE TABLETS 30 MG) (15000 with 4 shipments worth $57.8K.
How Does Aristo Pharmaceuticals Private Limited Compare to Nearest Pioglitazone Exporters?
Exporters ranked immediately above and below #9 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 7 | IND SWIFT LIMITED | $1.2M | 55 | 8 | $22.2K |
| 8 | MACLEODS PHARMACEUTICALS LIMITED | $1.2M | 106 | 1 | $11.5K |
| 9 | ARISTO PHARMACEUTICALS PRIVATE LIMITED ★ | $721.0K | 100 | 6 | $7.2K |
| 10 | DR.REDDY'S LABORATORIES LTD | $683.3K | 30 | 1 | $22.8K |
| 11 | MEDLEY PHARMACEUTICALS LIMITED | $616.1K | 78 | 2 | $7.9K |
Aristo Pharmaceuticals Private Limited ranks #9 among 115 Indian Pioglitazone exporters. Average shipment value of $7.2K compared to the market average of $305.7K. The closest competitors by value are IND SWIFT LIMITED and MACLEODS PHARMACEUTICALS LIMITED.
Which Indian Ports Ship Pioglitazone Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR | 249 | 9.3% |
| HYDERABAD ICD | 229 | 8.6% |
| DELHI AIR CARGO ACC (INDEL4) | 206 | 7.7% |
| SAHAR AIR | 205 | 7.7% |
| HYDERABAD ICD (INSNF6) | 203 | 7.6% |
| SAHAR AIR CARGO ACC (INBOM4) | 143 | 5.3% |
| MUNDRA SEA | 127 | 4.7% |
| CMA CGM LOGISTICS PARK ICD | 126 | 4.7% |
Geopolitical & Trade Policy Impact on Aristo Pharmaceuticals Private Limited's Pioglitazone Exports
The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like Aristo Pharmaceuticals. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended delivery times. Major shipping lines have implemented 'Emergency Risk Surcharges,' adding financial strain to exporters relying on these routes. Additionally, the U.S. has imposed tariffs on pharmaceutical imports, affecting the profitability of Indian exporters. However, the India–European Union Free Trade Agreement (FTA), concluded in January 2026, offers a silver lining. The FTA eliminates tariffs on Indian pharmaceutical products entering the EU, potentially boosting exports to this region. Aristo Pharmaceuticals can leverage this agreement to strengthen its presence in the European market, offsetting challenges in other regions.
Aristo Pharmaceuticals Private Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. Food and Drug Administration (FDA), World Health Organization (WHO), and European Union Good Manufacturing Practices (EU GMP) set stringent quality requirements. While specific compliance details for Aristo Pharmaceuticals are not publicly available, adherence to these standards is essential to maintain market access and credibility. The evolving regulatory landscape necessitates continuous investment in quality assurance and compliance infrastructure to meet the expectations of global markets.
About Aristo Pharmaceuticals Private Limited
Aristo Pharmaceuticals Private Limited exports 8 products worth $19.4M. Beyond Pioglitazone, top products include Telmisartan, Hydrochlorothiazide, Domperidone, Probiotics, Ambroxol. View the complete Aristo Pharmaceuticals Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Pioglitazone — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Pioglitazone shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Aristo Pharmaceuticals Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 100 individual customs records matching Aristo Pharmaceuticals Private Limited exporting Pioglitazone, covering 69 formulations to 6 countries via 7 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 70+ countries, 293+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Pioglitazone Export Data from Aristo Pharmaceuticals Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Aristo Pharmaceuticals Private Limited's Pioglitazone exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Aristo Pharmaceuticals Private Limited
Full Company Profile →
8 products · $19.4M total trade · 8 categories
Pioglitazone Stats
Company Overview
Top Products by Aristo Pharmaceuticals Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Aristo Pharmaceuticals Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Pioglitazone. For current shipment-level data, contact TransData Nexus.